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Chronic cardiac stress induces pathologic hypertrophy and ﬁbrosis of the myocardium. The
microRNA-29 (miR-29) family has been found to prevent excess collagen expression in
various organs, particularly through its function in ﬁbroblasts. Here, we show that miR-29
promotes pathologic hypertrophy of cardiac myocytes and overall cardiac dysfunction. In a
mouse model of cardiac pressure overload, global genetic deletion of miR-29 or antimiR-29
infusion prevents cardiac hypertrophy and ﬁbrosis and improves cardiac function. Targeted
deletion of miR-29 in cardiac myocytes in vivo also prevents cardiac hypertrophy and ﬁbrosis,
indicating that the function of miR-29 in cardiac myocytes dominates over that in non-
myocyte cell types. Mechanistically, we found cardiac myocyte miR-29 to de-repress Wnt
signaling by directly targeting four pathway factors. Our data suggests that, cell- or tissue-
speciﬁc antimiR-29 delivery may have therapeutic value for pathological cardiac remodeling
and ﬁbrosis.
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M icroRNAs (miRNAs) are short, non-coding RNAmolecules that regulate gene expression at the post-transcriptional level1, and serious estimates are that the
majority of genes and cellular processes are controlled by miR-
NAs or other non-coding RNA molecules2–4. miRNAs have
likewise been implicated in many diseases5, including those of the
cardiovascular system6. Of particular interest in this respect is
cardiac remodeling, a response of the myocardium to chronic
cardiac stress conditions, such as aortic stenosis, that is marked
by cardiac hypertrophy and ﬁbrosis. Hypertrophy and ﬁbrosis are
tightly interwoven, and mutually trigger each other7. Prominent
miRNAs with a documented role in cardiac myocyte hypertrophy
include miR-208, miR-133 and miR-212/1328–10, whereas a role
in ﬁbrosis has been demonstrated for miR-21, miR-30, miR-133,
and miR-2911–15. In this regard, miR-29 has been reported to be
downregulated in several ﬁbrosis-related diseases in rodents as
well as in humans, and has been shown to target mRNAs that
encode ﬁbrosis-promoting proteins in different cell types/
organs16–21. In apparent agreement with this, experimental ele-
vation of miR-29 was found to repress collagen transcripts in
cultured cardiac ﬁbroblasts13. Altogether, these ﬁndings sup-


































































































































































































Fig. 1 Genetic deletion of miR-29 in a mouse model for left ventricular pressure overload. a Expression of miR-29 family members in left myocardium from
wildtype (WT), miR-29 ab1−/− b2c+/− and miR-29 ab1+/+ b2c−/− mice; n= 4–6 mice/group. b Echocardiographic analysis of fractional shortening as a
measure of left ventricular function; n= 4–10 mice/group. A Student’s t-test was used to calculate the P values. c (Left) Representative stainings of
myocardial tissue from WT or knockout mice (tissue ﬁxation 21 days after sham surgery or transverse aortic constriction, TAC) by hematoxylin/eosin and
Sirius Red/Fast Green stainings. Scale bar: 2 mm. (Right) Ratio between heart weight and tibia length (HW/TL) as a measure of cardiac hypertrophy; n=
6–14 mice/group. P values were determined by two-way ANOVA followed by Bonferroni’s post hoc test. d (Left) Representative wheat germ agglutinin
(WGA)-staining of midventricular sections to assess hypertrophy of cardiac myocytes. Scale bar: 50 µm. (Right) Quantitative analysis; n= 5–8 mice/
group. P values were calculated using two-way ANOVA followed by Bonferroni’s post hoc test. e (Left) Representative image sections from Sirius Red/Fast
Green-stained myocardium of the indicated groups and (Right) quantitative analysis of ﬁbrosis; n= 3–11 mice/group. P values were determined by two-way
ANOVA followed by Bonferroni’s post hoc test. f Real-time PCR quantiﬁcation of markers for cardiac remodeling in left ventricular tissue from WT, miR-29
ab1−/− b2c+/− and miR-29 ab1+/+ b2c−/− mice. Collagen mRNAs and the following markers of cardiac myocyte hypertrophy were assessed: Nppa, atrial
natriuretic peptide;Myh7/Myh6, ratio of mRNAs encoding β- and α-myosin heavy chain. Tissues were collected 21 days after TAC surgery; data are from 4
to 9 independent experiments, with 2 replicates each. WT TAC means were compared to that of miR-29 ab1−/− b2c+/− and miR-29 ab1+/+ b2c−/− mice
by a one-way ANOVA followed by a Bonferroni’s post hoc test. *P< 0.05, **P< 0.01, ***P< 0.001 for all panels. All quantitative data are reported as
means± SEM
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anti-ﬁbrotic therapy for lung, liver, kidney and heart diseases. At
the same time, there are exciting reports about the ability of
speciﬁc miR-29 inhibitors (antimiRs) to prevent development or
progression of abdominal aortic aneurysms22–24. AntimiR-29 has
proven even more effective in this context than antimiRs against
another promising candidate, miR-19525.
Remarkably, the miR-29 family (i.e., miR-29a, b, and c) had
also emerged as a potent inducer of cardiac myocyte (CM)
hypertrophy from a phenotypic screen26. As this might have
consequences for the therapeutic use of miR-29, we set out to
elucidate the role of miR-29 in myocardial remodeling, and
manipulated miR-29 in primary CMs, as well as in vivo. Here, we
show that miR-29 promotes hypertrophic growth of cardiac
myocytes in vivo, together with an increase, rather than a
reduction, of cardiac ﬁbrosis. In support of this ﬁnding, phar-
macological inhibition or genetic deletion of miR-29 prevented
cardiac hypertrophy and ﬁbrosis in mice. miR-29 was further
characterized as a regulator of canonical and non-canonical Wnt
signaling in cardiac myocytes, thereby eliciting hypertrophy of
these cells and the secretion of proﬁbrotic proteins that signal
towards cardiac ﬁbroblasts (CF). This indicates a unique
hierarchy of miR-29 activities in cardiac cell types with respect to
cardiac remodeling, with effects of miR-29 in CM dominating
over its function in CF.
Results
Genetic deﬁciency of miR-29 prevents cardiac remodeling.
Starting from the observation that raising miR-29 levels and
activity by synthetic miR-29 molecules induced hypertrophy of
primary cardiac myocytes in vitro (Supplementary Fig. 1), we
asked whether inhibition or reduction of this miRNA was bene-
ﬁcial in cardiac disease models in vivo. We did not obtain mice
with complete genetic loss of both miR-29 clusters (miR-29, a/b1,
and b2/c), which is in good agreement with a recent report27,
according to which the offspring ratio was 1%, with those born
dying within few weeks. Therefore, we used mouse lines with
partial deﬁciency of miR-29 variants, that is, mice with miR-29
ab1−/− b2c+/− or ab1+/+ b2c−/− genotype. Again consistent with
other studies27–29, mice with triple-allelic deletion of miR-29
show some growth retardation (Supplementary Fig. 2a) and
increased mortality, whereas mice with miR-29 ab1+/+ b2c−/−
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Fig. 2 Pharmacological inhibition of miR-29 prevents cardiac remodeling and dysfunction. a (Left) Design of the miR-29 family inhibitor (antimiR-29).
Sequences of miR-29a, b1, b2 and c display a high degree of sequence similarity with identical seed regions (depicted in blue), thus permitting the design of
a single antimiR molecule. (Right) Design of the study. b Cardiac expression of miR-29 family members in mice, determined weeks after the ﬁrst injection
of antimiR-29, a control molecule (antimiR-Ctrl) or PBS. c Echocardiographic analysis of left ventricular fractional shortening in sham-/TAC-operated mice
3 weeks after injection with antimiR-29/-ctrl or PBS (determined by echocardiography), indicating reduced TAC effects in the antimiR-29-treated group. d
Heart weight-to-tibia length ratio and eWGA staining of left ventricular tissue from mice described in c for determination of cardiac and CM hypertrophy. f
(Left) Representative left ventricular sections stained with Sirius Red/Fast Green of the indicated treatment groups and (right) quantiﬁcation of interstitial
ﬁbrosis. g Quantitative real-time PCR analysis of molecular markers for cardiac myocyte hypertrophy (Nppa, Myh7/Myh6) and of ﬁbrosis-associated
collagens. All scale bars: 50 µm. All quantiﬁcations derive from n= 5–14 mice/group, PCR performed with 2 replicates each. All quantitative data in panels
c–g are reported as means± SEM. *P< 0.05, **P< 0.01, ***P< 0.001 determined by two-way ANOVA followed by Bonferroni’s post hoc test
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phenotypical effects as, for instance, in body weight nor was there
evidence for the induction of ﬁbrosis in other organs (Supple-
mentary Fig. 2b). Cardiac miR-29 levels (miR-29 referring here
and in the following to the respective 3p strands, as we found the
5p strands to be hardly expressed) in miR-29 ab1−/− b2c+/− or
ab1+/+ b2c−/− mice were reduced by 80% or 65%, respectively
(Fig. 1a), but–under basal conditions–this deﬁciency did not elicit
a cardiac phenotype (Fig. 1b–e). We then proceeded to test these
mice in a disease model for left ventricular pressure overload,
induced by transverse aortic constriction (TAC). TAC-treated
miR-29 ab1−/− b2c+/− or ab1+/+ b2c−/− mice showed a reduction
of miR-29 by 60% or 40%, respectively (Supplementary Fig. 3a).
Importantly, both mouse lines were protected from TAC-induced
cardiac hypertrophy and functional impairment, showing better
heart function than wildtype (Fig. 1b and Supplementary
Table 1), reduced myocardial (i.e., heart weight) and cardiac
myocyte hypertrophy (Fig. 1c, d) and lower levels of hypertrophy-
associated marker genes Nppa and Myh7 (in relation to Myh6)
(Fig. 1f). Remarkably, also myocardial ﬁbrosis was reduced in
these miR-29-deﬁcient mice, as determined by Sirius Red staining
of left ventricular sections (Fig. 1c, e) and by collagen expression
(Fig. 1f). Comparably minor effects were seen in Sham-treated
animals, where only two genes were modestly deregulated (i.e., 2-
fold for Col1a1, 0.5-fold for Col3a1 in miR-29 ab1−/− b2c+/− vs.
WT) and matrix staining with Sirius Red was found to be
unchanged (Fig. 1e).
AntimiR-29 protects against cardiac hypertrophy and ﬁbrosis.
To exclude that compensatory mechanisms in miR-29 ab1−/−
b2c+/− or miR-29 ab1+/+ b2c−/− mice had obscured additional
effects, we next sought to inhibit miR-29 acutely in the adult
animal. Three consecutive injections of a chemically modiﬁed
antisense oligonucleotide, designed to target all members of the
mouse miR-29 family (antimiR-29), lead to a 70% reduction of
myocardial miR-29 under basal conditions (Fig. 2a, b) and in the
TAC model (Supplementary Fig. 3b). This relative reduction was
observed in cardiac myocytes as well as in cardiac ﬁbroblasts
(Supplementary Fig. 3c). Consistent with our ﬁndings in miR-29-
deﬁcient mice, infusion of antimiR-29 protected from cardiac
dysfunction, cardiac hypertrophy at the tissue and cellular level,
and from ﬁbrosis (Figs. 2c–f and Supplementary Table 2). Like-
wise, the corresponding gene expression signatures revealed a
decrease of markers for hypertrophy (Nppa, Myh7) and ﬁbrosis
(Col1a1, Col1a2, Col3a1) (Fig. 2g). One study reported increased
perivascular ﬁbrosis upon application of a miR-29b inhibitor,
without affecting cardiac hypertrophy30. This could be due to
different oligonucleotide chemistries or the speciﬁc targeting of
variant miR-29b which, due to nuclear localization31,32, may have
functions other than, or in addition to, variants a and c. Because
of these unresolved discrepancies, and in view of the therapeutic
effects observed thus far, we chose to analyze in detail the
expression of miR-29 variants in healthy and diseased
myocardium.
The miR-29 family is dynamically regulated. By quantitative
real-time PCR analysis, we found myocardial levels of each miR-
29 variant strongly increased with age (Fig. 3a). This is consistent
with previous reports22,33 and interesting with regard to a pro-
posed function of miR-29 in body growth control33. Most
remarkable with respect to disease, however, are the temporal
changes in miR-29 expression that occur in mice subjected to
TAC. This model of pressure overload lead to a prominent
increase of cardiac myocyte miR-29 in the ﬁrst 48 h after surgery,
followed by downregulation in the late phase (Fig. 3b). Upon
isolation of myocytes and ﬁbroblasts from myocardium of these
mice, total as well as individual levels of miR-29 variants were
substantially (×6) higher in CM compared to CF (Fig. 3c). This
ﬁnding is remarkable, given previously reported, higher levels in
CF than in CM13. We identiﬁed a possible explanation for this





























































































































Fig. 3 Expression of miR-29 members in cardiac cells and their deregulation in disease. a–d Individual quantiﬁcations (by qPCR) of miR-29 variants a, b and
c in primary cardiac cells or in left ventricular myocardium. a Age-dependent cardiac expression of miR-29 variants in mice (w: week); n= 4–5 mice per
group. b Endogenous levels of miR-29 family members in cardiac myocytes from mice 21 days after sham treatment or, for the TAC group, at denoted time
points; n= 3–6 mice per group. c Endogenous levels of miR-29 family members in CM and CF freshly isolated from adult mouse myocardium; n= 12–13
independent cell isolations. d Quantiﬁcation of miR-29 variants in human left ventricular myocardium from 23 healthy individuals or from 24 patients with
aortic valve stenosis. All quantitative data are reported as means± SEM. ***P< 0.001 calculated using Student’s t-test
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cultivation: within one week of cultivation, an abnormal
and drastic upregulation of miR-29 occurred in primary CF
from neonatal rat as well as from adult mouse (Supplementary
Fig. 3d, e). Besides this cell culture-related phenomenon in CF,
the high endogenous expression of all miR-29 variants in CM
suggests a role in this cell type. Interestingly, downregulation of
miR-29a and miR-29b in chronic myocardial disease was not only
observed in the murine disease model, but also in myocardium
from patients with aortic valve stenosis (Fig. 3d). In line with this,
a recent HITS-CLIP analysis of Argonaute protein 2 (Ago2)-
bound RNAs in human myocardium found miR-29 targets to be
enriched in this context34. Altogether, these ﬁndings prompted us
to investigate the role of miR-29 speciﬁcally in CMs in adult
animals.
Cardiac myocyte-speciﬁc deletion of miR-29 in vivo. To
manipulate miR-29 speciﬁcally in CM in vivo, we used adeno-
associated virus serotype 9 (AAV9), which targets almost exclu-
sively CMs within the myocardium15. In order to genetically
inactivate miR-29 speciﬁcally in CMs in vivo, we infected mice
that carry ﬂoxed alleles of the miR-29b2c locus (miR-29 b2cﬂ/ﬂ)
with an AAV9 vector that encodes for improved Cre recombinase
(iCre) (Fig. 4a). Treatment with AAV9-iCre reduced myocardial
levels of miR-29b and c to approx. 50% (Fig. 4b) and signiﬁcantly
prevented left ventricular dysfunction (Fig. 4c and Supplementary
Table 3), myocardial hypertrophy (Fig. 4d) and interstitial ﬁbrosis
(Fig. 4e). Altogether, targeted deletion of miR-29 in cardiac
myocytes phenocopied pharmacological inhibition or global
genetic deletion of miR-29.
As a reciprocal strategy, we adopted our previous approach for
AAV9-mediated expression of a microRNA35. Upon injection of
AAV9-miR-29a (or an AAV9 that encodes the nonrelated C.
elegans miR-39) into 5 week-old mice (Supplementary Fig. 4a),
we observed a 3-fold increase in myocardial miR-29a (compared
to control, Supplementary Fig. 4b) that was speciﬁc for
myocardium and therein for CMs (Supplementary Fig. 4c, d).
Under TAC, AAV9-miR-29a mice show enhanced myocardial
and CM hypertrophy (Supplementary Fig. 4e, f). In addition,
cardiac ﬁbrosis was moderately (yet not signiﬁcantly) increased
without overt cardiac dysfunction (Supplementary Fig. 4g and
Supplementary Table 4), which we attribute to the high
endogenous miR-29 levels in adult mice (Fig. 3a) and the
expected ceiling effect of further experimental elevation.
Together, the complementary ﬁndings from CM-speciﬁc deletion
or augmentation of miR-29 suggest a dominant role of miR-29 in
CM over that in CF.
miR-29 de-represses Wnt signaling in cardiac myocytes. To
assess whether miR-29 levels in cardiac myocytes correlate with
proﬁbrotic signaling, we analyzed the secretome of primary car-
diac myocytes after manipulation of miR-29. CMs were trans-
fected with antimiR-29 or a control antimiR, and proteins from
the culture supernatant were isolated and analyzed by mass
spectrometry (Fig. 5a). As shown in Fig. 5b, we identiﬁed several
factors with documented proﬁbrotic function that were reduced
in the secretome of antimiR-29-treated CM. Importantly, among
the deregulated genes, we found those enriched that have binding
sites for TCF/LEF or NFAT (Fig. 5c). The presence of such
binding sites marks genes as endpoints of the Wnt/frizzled sig-
naling pathway36. Indeed, primary CM after transfection with a
miR-29 mimic showed activation of both Wnt ligand-induced
and NFAT pathways (Fig. 5d), the latter suggestive of non-
canonical Wnt signaling. Since these data suggested that miR-29
may act as a general regulator of Wnt signaling, we further
analyzed whether (or which of its) intracellular pathway factors
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Fig. 4 Deletion of miR-29 in cardiac myocytes in vivo protects from cardiac remodeling. Tropism of adeno-associated virus 9 for cardiac myocytes in vivo
was employed to deliver improved Cre recombinase (AAV9-iCre) to miR-29 b2cﬂ/ﬂ mice for the deletion of this cluster (with miR-29 b2c+/+ littermates
serving as controls). a Design of the study. 5 × 1011 viral particles (AAV9-iCre) were delivered to 5 day-old mice via intrapericardial injection. Seven weeks
later, mice were subjected to TAC or sham surgery and sacriﬁced another 3 weeks later (after echocardiographic analysis). b Expression of miR-29b and
miR-29c in cardiac tissue from mice treated as in a; n= 4–6 mice per group. c Left ventricular fractional shortening as determined by echocardiographic
analysis; n= 4–8 mice per group. d (Left) Representative hematoxylin eosin stainings of myocardial sections; scale bar= 2 mm. (Right) Heart weight-to-
tibia length ratio; n= 4–11 mice per group. e (Left) Representative myocardial sections stained for ﬁbrosis with Sirius Red/Fast Green and (right)
quantitative analysis of the results; n= 4–9 mice per group; scale bar: 2 mm. All quantitative data are reported as means± SEM. *P< 0.05, **P< 0.01,
***P< 0.001 as determined by Student’s t-test b or two-way ANOVA followed by Bonferroni’s post hoc test c–e
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Wnt pathway contain binding sites for miR-29, namely GSK3B,
ICAT/CTNNBIP1, HBP1 and GLIS2. 3′-UTR reporter activity
assays (including also control constructs with mutated miR-29
binding sites) identify them as direct targets of miR-29 (Fig. 5e).
To assess the functional relevance of the Wnt pathway in med-
iating the prohypertrophic effects of miR-29, we tested whether a
small molecule Wnt pathway inhibitor (IWR-1) would interfere
with miR-29-induced cardiac myocyte hypertrophy. Consistent
with our earlier ﬁndings, elevation of miR-29 levels induced
hypertrophy of primary cardiac myocytes, yet IWR-1 largely
abrogated the prohypertrophic effect of miR-29 (Fig. 5f). The role
of miR-29 as a mediator of NFAT activation became further
evident by decreased NFAT-dependent transcriptional activation
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antimiR-29 or miR-29-deﬁcient mice after TAC (Supplementary
Fig. 5a), and by the ﬁnding that addition of the NFAT inhibitor
VIVIT to cultured CM prevents miR-29-induced cardiac myocyte
hypertrophy (Supplementary Fig. 5b).
Altogether, these data demonstrate a critical regulation of
canonical and non-canonical Wnt signaling in cardiac myocytes
through miR-29 (Fig. 5g). Our data are also in agreement with
recent HITS-CLIP data34 showing that GSK3B and other factors
involved in remodeling events in cardiac myocytes are targets of
miR-29 in diseased human myocardium. Given that Wnt
signaling in CM is increasingly appreciated as a driver not only
of cardiac hypertrophy, but also of ﬁbrosis36–38, our data suggest
a dominant pro-hypertrophic effect in myocardium that is
regulated by miR-29.
Discussion
In this study, we demonstrate a role of the miR-29 family in
pathologic hypertrophy of the myocardium and ﬁbrosis. These
processes of cardiac remodeling occur in response to chronic
cardiac stress, and we show here that inhibition or genetic deﬁ-
ciency of miR-29 protects from cardiac hypertrophy and ﬁbrosis
in a mouse model for chronic cardiac pressure overload. In a
previous study, we had singled out variants miR-29a and c by
phenotypic library screening as potential prohypertrophic
microRNAs26. The present study substantiates and extends this
early observation and identiﬁes cardiac myocyte miR-29 to exert a
key role in cardiac remodeling. We show that, in myocardium,
miR-29 is prominently expressed in cardiac myocytes (CM) and
that CM-speciﬁc genetic deﬁciency of miR-29 in vivo signiﬁcantly
reduced the development of pressure overload-induced cardiac
hypertrophy (while, consistently, overexpression in CM in vivo
exerted the opposite effect). Intriguingly, analysis of proteins
secreted by CM and their validation by 3′ UTR reporter assays
suggested that miR-29 exerts these effects, at least in part, by
direct regulation of factors of the Wnt signaling pathway.
The Wnt pathway stands out from most other signaling cas-
cades, because its activation occurs by liberation from constitutive
inhibition (upon reducing beta-catenin degradation39). Our data
suggest that the effects of miR-29 on the Wnt cascade occur by
repressing several factors that constitute this inhibition (Fig. 5g):
(i) GSK3B, the function of which is to commit beta-catenin to
degradation and which, in mice transgenic for its hyperactive S9A
mutant, protects from TAC-induced cardiac hypertrophy40,41, (ii)
CTNNBIP1 (also known as ICAT), a protein that blocks activated
beta-catenin from interacting with the transcription factor TCF/
LEF, and deﬁciency of which causes heart enlargement42, (iii)
HBP1, a negative regulator of TCF/LEF43 and (iv) GLIS2, a
transcriptional repressor that binds to, and is cleaved by, p120
catenin44. We propose the beneﬁcial effect exerted by antimiR-29
to result to a considerable extent from restoration of the inhibi-
tion of Wnt signaling. Formal proof for this hypothesis would
require the inhibition of Wnt-signaling together with manipula-
tion of miR-29 in cardiac myocytes in vivo, which should be the
focus of further studies. Of note in this respect, the data presented
here also support a previously suspected correlation between
miR-29 and Wnt signaling in osteoclasts45.
An unexpected outcome of our studies in the pressure overload
model was that antimiR-29 not only prevented cardiac hyper-
trophy, but also cardiac ﬁbrosis. This is a remarkable ﬁnding,
considering that elevation, rather than inhibition, of miR-29
suppresses ﬁbrosis in tissues other than myocardium. Fibrosis—
the secretion of extracellular matrix proteins such as collagens—
occurs in response to various disease conditions. Based on target
prediction algorithms, miR-29 has early been suspected to
negatively regulate the expression of collagens and, indeed, this
has been conﬁrmed by manipulating miR-29 in vitro or in various
tissues13,30. More importantly, studies on miR-29 in ﬁbrosis
disease models in liver, lung and kidney have demonstrated the
potential beneﬁt of elevating miR-29 levels46–48. In this respect,
our ﬁndings that inhibition or genetic deﬁciency of miR-29
in vivo prevents (rather than promotes) myocardial ﬁbrosis in a
cardiac disease model were, at ﬁrst, unexpected. We thus rea-
soned that the unique myocardial tissue context may determine
the net balance of pro- or antiﬁbrotic miR-29-controlled pro-
cesses more than its individual activity in cardiac ﬁbroblasts. The
hypothesis of a dominant miR-29 function in CM ﬁnds support
by our observations that (i) endogenous levels of miR-29 variants
in vivo are substantially higher in CM, compared to CF (a dis-
crepant previous observation in cultured CF13 seems attributable
to aberrant expression that occurs during cultivation, see Sup-
plementary Fig. 3d, e), that (ii) mice with CM-speciﬁc deﬁciency
for the miR-29b2/c cluster (upon infection with iCre-encoding
AAV9 vector) were largely protected from pressure overload-
induced cardiac remodeling (consistently, AAV9-mediated
overexpression exacerbated cardiac remodeling in this model)
and that (iii) induction of ﬁbrosis-involved collagens 1a1, 1a2 and
3a1 in TAC-exposed myocardium is reduced in miR-29-deﬁcient
or antimiR-29-treated mice (Figs 1f, 2g). Together, these data
illustrate a function of miR-29 in the interplay between myo-
cardial cell types that promote cardiac remodeling, and highlights
a perspective for therapeutic inhibition of miR-29. Interestingly,
inhibiting miR-29 may also prove beneﬁcial in limiting aortic
aneurysm progression22 and our data should prove valuable also
with regard to the further development of this indication. Future
Fig. 5 miR-29 targets key components of the Wnt signaling pathway. a Design of the study. b Volcano-plot of fold changes of individual proteins from
NRCM transfected with antimiR-29 or antimiR-ctrl. Dark gray symbols highlight signiﬁcantly deregulated proteins (P< 0.05) and orange symbols those
with known or predicted proﬁbrotic function. LUM Lumican, CTSL Cathepsin L, LGALS3BP Galectin 3 Binding Protein, CST3 Cystatin C, CDH2 Cadherin 2,
ECM1 Extracellular Matrix Protein 1, APP Amyloid Beta Precursor Protein. c Signiﬁcant GO enrichment of transcription factor binding sites in the
deregulated secreted factors. d (Left) Wnt activity using a TCF/LEF reporter assay in NRCM 48 h after transfection with miR-29a or miR-ctrl. (Right) NFAT
activity in NRCM 48 h after transfection with miR-29a miR-ctrl; 4–5 independent experiments in triplicate. e miR-29 directly regulates the Gsk3β, Ctnnbip1,
Hbp1 and Glis2 3´-UTRs. HEK293 cells were transfected with miR-29a or miR-ctrl. Ratiometric analysis of ﬂuorescent emissions from a dual ﬂuorescent
reporter carrying the Gsk3β, Ctnnbip1, Hbp1 and Glis2 3´-UTRs or seed mutants. Data are from 8 independent experiments performed in triplicate. f The
Wnt-inhibitor IWR-1 (10 μM for 96 h) prevented miR-29-induced cardiac myocyte hypertrophy. (Up) Representative segmentation images of NRCM
transfected with either miR-29 or miR-ctrl in the presence or absence of IWR-1 scale bar: 100 μm. NRCM were identiﬁed based on α-actinin detection
(green) and are assigned green nuclei, whereas non-myocytes were assigned red nuclei. (Down) Quantitative analysis of the results. Data are from four
independent experiments performed in triplicate. g Proposed mechanism how miR-29 promotes Wnt signaling in CM and signals to ﬁbroblasts. In cardiac
myocytes, miR-29 (by targeting Gsk3b Ctnnbip1, Hbp1 and Glis2) activates the Wnt signaling pathway, as well as NFAT activity. Activation of Wnt and NFAT
signaling pathways promotes cardiac myocyte hypertrophy and secretion of proﬁbrotic factors, which act in cardiac ﬁbroblasts. Pharmacological inhibition
or genetic deletion of miR-29 in cardiac myocytes prevents cardiac hypertrophy and ﬁbrosis. All quantitative data are reported as means± SEM. *P< 0.05,
**P< 0.01, ***P< 0.001 as determined by Student’s t-test d, e or two-way ANOVA followed by Bonferroni’s post hoc test f
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studies will expand our understanding of which mechanisms are
involved in miR-29 mode of action in cardiac ﬁbroblasts. These
studies should identify how miR-29 inhibition prevents cardiac
ﬁbrosis in vivo and determine the relevance of the Wnt signaling
pathway in this anti-ﬁbrotic effect. In light of the dynamic reg-
ulation of miR-29 observed after initiation of pressure overload in
this study, the timing and duration of therapeutic miR-29 inhi-
bition may warrant optimization as well as long term follow-up.
Whether the miR-29 family members exert individual roles in
myocardium and to what extent there is functional redundancy
among them has not been resolved yet. Given the reported
nuclear localization of miR-29b31,32, it is well conceivable that
this variant could have functions in addition to those of miR-29a
and c. This may also explain (next to differing experimental
conditions) why a previous study observed increased left ven-
tricular ﬁbrosis in TAC-treated, antimiR-29b-infused mice
(compared to antimiR-control)30. Also, endogenous expression
levels of each family member appear to vary, depending on
experimental conditions and time points analyzed13,23,30. Thus,
an even deeper comparison of miR-29 expression in cell types,
organs and disease models may be rewarding in order to dissect
individual functions of each variant.
The prohypertrophic function of miR-29 in CM and the pro-
ﬁbrotic effect that comes with it provokes to ask whether global
genetic deﬁciency of miR-29 (miR-29 ab1−/− b2c+/− mice) or
systemic antimiR-29 infusion induced ﬁbrosis in organs such as
kidney, liver or lung. We have not observed an increase of Sirius
Red staining for extracellular matrix in miR-29 ab1−/− b2c+/−
mice in these organs (Supplementary Fig. 2b). Nonetheless, to
minimize the risk of unwanted side effects in these organs, miR-
29-directed therapy against cardiac remodeling would likely
beneﬁt from targeted delivery to the myocardium and individual
cell types therein - developments that are still in their infancy49,50.
The unveiled unique hierarchy of miR-29 activities in different
cardiac cell types in myocardium now provides a basis for such
approaches.
Methods
Mouse models. Thoracic aortic constriction was performed on 8-week-old male
C57BL/6 N mice (Charles River Laboratories), as described51 with small adapta-
tions. Mice received buprenorphine (0.1 mg/kg s.c.) 60 min before intubation and
anesthesia with isoﬂurane. Thoracotomy was performed between the second and
third rib, and the aortic arch was narrowed by a ligature over a 27 G cannula. Until
complete recovery from anesthesia, the mice remained in a warmed cage for 2–4 h
under direct supervision. In sham surgery, only the chest was opened, but no
ligation of the aorta was carried out. Cardiac dimensions and function were ana-
lyzed by pulse-wave Doppler echocardiography, before TAC/sham surgery and
before the animals were euthanized. Then, mice were sacriﬁced to determine
parameters of cardiac hypertrophy and ﬁbrosis. The generation of miR-29ab1−/−
mice has been described previously28. Hemizygous miR-29b2/cﬂ/+ animals were
generated as follows: for the targeting construct, two homologous arms of the ~
10 kb miR-29b-2/c cluster KpnI fragment were isolated and ampliﬁed from 129/Ola
genomic DNA and inserted in a diphtheria toxin-A (DT-A)-containing pUC18
vector52. 0.4 kb downstream of miR-29c (SphI) as well as upstream of miR-29b-2
(NheI), two mutated loxP sites53 were inserted, the latter followed by a PGK-
driven, FRT ﬂanked hygromycin B cassette. After linearization (XmaI) and elec-
troporation of the targeting construct to E14 129/Ola ES cells, clones resistant to
hygromycin B (at 60 µg/ml) were screened by Southern blotting, followed by PCR
and sequencing. Chimera obtained by morula aggregation were back-crossed at
least 7 times in C57BL/6 background. Homozygous miR-29b2/cﬂ/ﬂ were crossed
with the EIIa-Cre line54 to produce full knockouts. All genotypes were veriﬁed by
PCR analysis. For cardiotropic expression of exogenous miR-29, 5-week-old male
wildtype mice received AAV9-miR-29a (2 × 1012 genome copies per mouse) or an
AAV9 that encodes the nonrelated C. elegans miR-39 (as a negative control) by tail
vein injection, and TAC was performed 3 weeks later. miR-29 b2cﬂ/ﬂ and miR-29
b2c+/+ neonatal mice were injected with AAV9-iCre as described previously15.
Brieﬂy, 3–4 day old mice were anesthetized by an injection of fentanyl (0.05 mg/
kg), midazolam (5 mg/kg) and medetomidine (0.5 mg/kg). Under anesthesia the
mice were injected 50 µl of the virus pericardially using a 30 G needle. Control
antimiR and antimiR-29 (synthesized by Exiqon, see Fig. 2a for sequence) were
administered intravenously at 20 mg/kg. Mice treated with PBS were also included
as controls. Cardiac dimensions and function were analyzed by pulse-wave
Doppler echocardiography before surgery and before the animals were euthanized.
All animal studies were approved by the relevant authority (Regierung von
Oberbayern, Munich, Germany) and performed in accordance with the relevant
guidelines and regulations.
Quantiﬁcation of miR-29 in human myocardium. Informed consent was
obtained from all subjects and the study was performed with the approval of the
institutional ethical committees of the University of Würzburg, Germany, and the
Hannover Medical School, Hannover, Germany. RNA from healthy human hearts
was purchased from Biochain Institute. We analyzed cardiac tissue from patients
undergoing aortic valve replacement because of aortic stenosis (N= 24, mean age
69.5 ± 18.19, male: female 16:8). For comparison, tissue of healthy human hearts
was used (N= 23, mean age 38.61± 12.96, male: female 14:9). Cardiac biopsies
were obtained from the left ventricle and frozen in liquid nitrogen. RNA was
isolated using TriFast. Expression of miR-29a, b and c and RNU6B (normalization
control) were measured by Taqman assays (ThermoFischer Scientiﬁc) as per
manufacturer’s instructions.
Isolation of cardiac myocytes and cardiac ﬁbroblasts. Neonatal rat cardiac
myocytes (NRCMs) and cardiac ﬁbroblasts (NRCFs) were isolated from 0–1-day-
old Sprague Dawley rats as described previously26. Brieﬂy, the area close to the
neck was disinfected and the rats were decapitated. The hearts were then excised
and digested with collagenase type II (Worthington) and pancreatin (Sigma
Aldrich) in CBFHH buffer (120 mM NaCl, 5 mM KCl, 0.8 mM MgSO4, 0.5 mM
KH2PO4, 0.3 mM Na2HPO4, 20 mM HEPES, 5.6 mM Glucose, pH 7.3 including
Penicillin/Streptomycin) at 37 °C. Every 10 min the solution containing the
digested cells was transferred to a new tube containing FCS (Sigma Aldrich). The
remaining not dissociated tissue residue was supplemented with fresh enzymatic
solution for additional ﬁve rounds. After combining the cell suspensions, they were
centrifuged at 50×g for 5 min and the pellet was resuspended in MEM medium
containing 5% FCS, ﬁltered (40 μm ﬁlter; BD), and pre-plated at 37 °C and 1% CO2
for 75 min onto 10 cm cell culture dishes (Nunc). Afterwards the supernatant
containing the cardiac myocytes was collected, the cells were counted automatically
(Countess Cell Counter, Invitrogen) and plated. Adult mouse cardiac myocytes
(AMCMs) and cardiac ﬁbroblasts (AMCFs) were isolated from wildtype C57BL/
6 N mice. Brieﬂy, hearts were excised and the aorta was cannulated and perfused
with buffer A (in mM: 113 NaCl, 4.7 KCl, 0.6 KH2PO4, 0.6 Na2HPO4, 1.2 MgSO4,
12 NaHCO3, 10 KHCO3, 10 HEPES, 30 taurine). For dissociation of cells col-
lagenase type II (Worthington) was included in the buffer. After dissociation the
cell suspension was incubated for 10 min at 37 °C, allowing the cardiac myocytes to
sediment. Afterwards the cardiac ﬁbroblast-enriched supernatant and the pellet
were resuspended in buffer B (47.5 ml perfusion buffer A, 2.5 ml FCS, 62.5 ml
10 μM CaCl2). Calcium reconstitution of cardiac myocytes was achieved by
addition of increasing concentrations of CaCl2 to a ﬁnal concentration of 100 µM.
The cardiac myocyte fraction was seeded in MEM (5% FCS, 10 mM 2,3-butane-
dione monoxime, 2 mM L-glutamine and 1% penicillin/streptomycin) at 37 °C and
5% CO2. For cardiac ﬁbroblast cultures, the supernatant was centrifuged for 5 min
(400 x g), resuspended in 5% FCS MEM culture medium and plated on 6 cm
culture dishes.
Histochemical and immunohistochemical analyses. Fixation of tissues for his-
tology was in 4% paraformaldehyde. Tissue slices(6 µm) were then processed for
hematoxylin/eosin staining. To determine collagen deposition, Sirius Red and Fast
Green staining was performed on parafﬁn sections (8 µm thick) of murine hearts.
The percentage of Sirius Red positive area was used as a quantitative measure of
collagen deposition. For determination of cardiac myocyte cross-sectional areas, 6
µm thick parafﬁn-embedded sections were prepared from murine hearts and
subsequently stained with Alexa Fluor 647-conjugated wheat-germ agglutinin
(WGA, Life Technologies, 1:200 dilution) for cell border determination and
SYTOX Green (Life Technologies, 1:1000 dilution) for nuclei detection. Images
were taken from areas of transversely cut muscle ﬁbers by confocal microscopy. A
Leica TCS SP5 II confocal microscope with a ×20 objective, laser lines 488 nm for
SYTOX Green and 633 nm for WGA were used for image acquisition. The
MetaMorph software (Molecular Devices) was programmed to recognize indivi-
dual cells based on the WGA staining in an automated fashion. Proper thresholds
were set for background and excessive ﬁbrosis exclusion. MetaMorph’s integrated
morphometry analysis tool was then used to calculate the average cell area of the
cardiac myocytes.
Quantitative real-time PCR. Total RNA was isolated using the RNeasy Mini kit
(Qiagen) and Superscript II (Invitrogen) was used to retrotranscribe 500 ng of RNA
following the manufacturer’s instructions. For quantitative real time PCR the
FastStart universal SYBR Green Master Mix (Roche) was used. Target-speciﬁc
primers were designed and their sequences are listed below (each gene symbol is
followed by the forward and reverse primers. In total 2 µl template, 400 nM primers
and 1× SYBR Green master mix were pippeted together and the qPCR was per-
formed in a StepOnePlus Real-Time-PCR System (Applied Biosystems).
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Quantiﬁcation of miR-29 in isolated cells or tissue. Total RNA was prepared
using TriFast (peqLab) and 10 ng were reverse-transcribed, using the Universal
cDNA Synthesis Kit II (Exiqon). The cDNAs were quantiﬁed using the FastStart
universal SYBR Green Master Mix (Roche), and modiﬁed primers for individual
miR-29 variants (miRCURY LNA PCR primer sets) or for U6 snRNA (Exiqon)
were used for qPCR quantiﬁcation in a StepOnePlus Real-Time-PCR System
(Applied Biosystems), with parameters recommended by Exiqon. For qPCR ana-
lysis, individual primer efﬁciencies were determined using a regression model
(LinRegPCR software), and analyses were done using the Pfafﬂ method.
Assessment of cardiac myocyte hypertrophy. NRCMs were plated onto optics-
optimized 96-well plates (Ibidi, Martinsried, Germany) in MEM medium that
contained 1% FCS. Twenty-four hours later, cells were transfected with miRNA
mimics (Ambion) or inhibitors (Exiqon) at a ﬁnal concentration of 50 nM, using
Lipofectamine2000 (Invitrogen). After 6 h of transfection, the medium was
exchanged to 0.1% FCS in MEM medium. Forty-eight hours later, the medium was
exchanged to 0.1% FCS in MEM, supplemented with or without phenylephrine to
50 µM (PE; Sigma-Aldrich). After 96 h of transfection, cells were washed twice with
PBS and ﬁxed for 10 min with paraformaldehyde (4%). When IWR-1 (Sigma-
Aldrich, 10 µM) or 11R-VIVIT (Calbiochem, 5 µM) was used, it was added to the
medium 6 h after transfection. Immunostainings of NRCMs in 96-well format and
automated cell size measurement were performed as described previously26. Cells
were ﬁxed using 4% paraformaldehyde (5 min at room temperature) and per-
meabilized with Triton-X (0.2% in PBS). The anti-α-actinin antibody (monoclonal,
sarcomeric, clone EA-53, Sigma Aldrich) in a 1:1000 dilution was then incubated
for 45 min at 37 °C, followed by incubation at 37 °C for 30 min with an Alexa-488-
coupled antibody (1:200 dilution, Invitrogen) and 4′,6-diamidin-2-phenylindol
(DAPI) (ﬁnal concentration 1 µg/µl, Sigma Aldrich). Cardiac myocytes were
assigned green, whereas non-myocytes are identiﬁed by red nuclei.
Reporter activity assays. NFAT activity was detected by luminescence using a
luciferase reporter construct containing NFAT binding sites (a kind gift from J.
Molkentin, University of Cincinatti). In order to test miR-29 mimic efﬁciency in vitro,
a complementary binding site for miR-29c was inserted into a pmiR-RL-TK2 vector
(a kind gift from G. Meister, University of Regensburg), downstream of the sequence
that encodes ﬁreﬂy luciferase. NRCMs were transfected with the reporter plasmids
and a miR-control or miR-29a (ﬁnal concentration 50 nM) using Lipofactamine2000
(Invitrogen) as recommended by the manufacturer. Fireﬂy and renilla luciferase
activities were determined using One-Glo or Dual-Glo luciferase assay kits (Promega)
according to the manufacturer’s instructions. For NFAT activity assays, the level of
luciferase activity was normalized to the total protein content.
Wnt activity was detected by luminescence using a luciferase reporter construct
containing binding sites for TCF/LEF (M50 Super 8x TOPFlash, Addgene plasmid
# 12456)55. A plasmid carrying mutated TCF/LEF binding sites upstream of a
luciferase reporter was used as a control (M51 Super 8x FOPFlash, Addgene
plasmid # 12457)55. NRCMs were transfected with the reporter plasmids and a
miR-control or miR-29a (ﬁnal concentration 50 nM) using Lipofectamine2000
(Life Technologies) as recommended by the manufacturer. Six hours before the end
of the experiment Wnt3a (Cell Guidance Systems Ltd) was added to the medium at
a ﬁnal concentration of 50 ng/ml. Luciferase activity was determined using One-
Glo luciferase assay kits (Promega) according to the manufacturer’s instructions.
In order to test if miR-29 directly targets Gsk3β, Ctnnbip1, Hbp1 and Glis2,
430–1240 base pairs of their 3′ untranslated regions (3′ UTRs; including the miR-
29 binding sites therein) were ampliﬁed by PCR and cloned into a double
ﬂuorophore-encoding plasmid. These plasmids contain the 3′-UTRs of the Gsk3β,
Ctnnbip1, Hbp1 and Glis2 genes downstream of the eGFP gene under the control of
the CMV promoter. As an internal control for transfection, the reporter construct
also comprised the tdTomato gene under a second CMV promoter, and data were
assessed as the ratio of both ﬂuorescence intensities. Mutation of miR-29 binding
site was carried out with primers carrying the nucleotide exchanges, using the Q5
site-directed mutagenesis kit (New England Biolabs). HEK293 cells were cultured
in modiﬁed Eagle medium (MEM) with 5% fetal calf serum (FCS). Plasmids were
co-transfected into HEK293 cells, using Lipofectamine2000 (Life Technologies) as
recommended by the manufacturer, with miR-ctrl or miR-29a (5 nM, Ambion) in a
96 well plate (Ibidi) and ﬂuorescence intensities measured 48 h later.
Construction and production of AAV9 vectors. A genomic fragment containing
700 nucleotides of the miR-29a precursor was ampliﬁed by PCR from mouse
genomic DNA and cloned into a self-complementary AAV backbone plasmid. The
C. elegans miR-39 (350 nucleotides) was synthesized, inserted in the AAV back-
bone plasmid and used as a control. The open reading frame of codon-improved
Cre-recombinase (iCre) was subcloned into a predigested self-complementary
AAV vector (scAAV-CMV).
HEK293-T cells were grown in triple ﬂasks for 24 h (DMEM, 10% fetal bovine
serum) before transfection. The transgene plasmid and the helper plasmid
(pDP9rs, kindly provided by Roger Hajjar, Icahn School of Medicine at Mount
Sinai, New York) were transfected into the HEK293 cells using Polyethylenimine
(Sigma-Aldrich). After 72 h, the viruses were puriﬁed from benzonase-treated cell
crude lysates over an iodixanol density gradient (Optiprep, Sigma-Aldrich). AAV
titers were determined by a real-time polymerase chain reaction (PCR) on vector
genomes using the SYBR Green Master Mix (Roche).
Secretome analysis. Neonatal rat cardiac myocytes (NRCM) were isolated and
seeded in a 6 well plate. One day later, NRCMs were transfected with LNA-
modiﬁed antimiR-29 or a control molecule (both from Exiqon) at a ﬁnal con-
centration of 50 nM, using Lipofectamine2000 (Life Technologies). After 6 h of
transfection, the medium was exchanged to 0.1% FCS in MEM medium. After 48 h,
the conditioned medium was collected and centrifuged at 3000 g for 10 min to
remove cell debris. The supernatant was transferred into a new tube and stored at
−80 °C. Conditioned media (2 ml each) were concentrated into 100 μl using 3 kD
MWCO spin column and 30 μl was mixed with 4× Laemmli buffer and proteins
were separated by 4–12% Bis-Tris gel at 130 V for 1.5 h. The gels were silver stained
and each lane was cut into 12 bands without any gap. The gel bands were digested
overnight on a ProGest robotic digestor. The digested peptides were lyophilized
and resuspended in 20 μl of 2% ACN, 0.05% TFA. Then 15 μl of peptides were
separated by reversed phase nano-ﬂow HPLC (UltiMate 3000 RSLCnano system
with PepMap C18 column, 25cm x 75 μm) (LC gradient: 0–5 min, 2–10%B;
5–65 min, 10–30%B; 65–70 min, 30–40%B; 70–80 min, 99%B; 80–100 min, 2%B; A
= 0.1% FA in HPLC H2O; B= 80% ACN, 0.1% FA in HPLC H2O) and directly
analyzed by LTQ Orbitrap XL using full ion scan mode m/z range 350–1600 with
Orbitrap, resolution 60000 (at m/z 400), lock mass m/z= 445.12003. MS/MS was
performed using CID on the top six ions with dynamic exclusion for 120 s.
Raw ﬁles were searched against UniProt/SwissProt rat database (2014_01, 7894
protein entries), using Mascot 2.3.01. The mass tolerance was set at 10 ppm for the
precursor ions and at 0.8 Da for fragment ions. Carboxyamidomethylation of
cysteine was used as a ﬁxed modiﬁcation and oxidation of methionine, proline and
lysine as variable modiﬁcations. Trypsin was used as enzyme and 2 missed
cleavages were allowed. Search results were loaded into Scaffold (version 4.3.2) and
the following ﬁlters were used: peptides probability > 95%, protein probability>
99%, minimum 2 unique peptides identiﬁed. The normalized spectrum count was
used for further analysis.
Statistics. The GraphPad Prism software (version 6) was used for all statistical
tests. The distribution of the data was determined by Shapiro Wilk’s or
Kolmogorov-Smirnov test for normality. F-test or Bartlett’s test was used to test for
common variance. All quantitative data are reported as means± SEM. The Stu-
dent’s t-test assessed differences between two means. If multiple means had to be
assessed, one-way or two-way ANOVA followed by Bonferroni’s post hoc test were
performed. If the n number was not sufﬁcient for normality testing, non-
parametric tests (Mann–Whitney U-test or one-way ANOVA followed by Dunn’s
test analysis) were used. Any P value less than 0.05 was considered to be signiﬁcant
and denoted as * for P< 0.05, ** for P< 0.01 and *** for P< 0.001. Not signiﬁcant
differences are abbreviated as “N.S.”.
Data availability. All data generated or analyzed during this study are presented in
this article and its Supplementary Information File, or are available from the
corresponding author upon reasonable request.
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